NCT02174419Phase 2, phase 3Completed

Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2016-08Actual

Enrollment · participants62Actual

Source updated2025-05-21Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Prurigo Nodularis; Nodularis Prurigo; Prurigo; Pruritus

Treatments or interventions studied

nalbuphine HCl ER tablets 90 mg BIDDrugAlso known as nalbuphine ER
nalbuphine HCl ER tablets 180 mg BIDDrugAlso known as nalbuphine ER
Placebo tablets BIDDrugAlso known as sugar pill

Primary outcomes · main study measures

measure: Change From Baseline to the Evaluation Visit (Week 10) in Itch on the 0-10 Numerical Rating Scale; description: The number of subjects who reported at least a 30% reduction from baseline to Week 10, expressed as a percentage of subjects in the particular arm/group who were evaluated,; timeFrame: Baseline, Week 10

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history